Status:
COMPLETED
Multiple Sclerosis: Chi3L1 and Treatment Efficacy
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-55 years
Brief Summary
Chitinase 3-like 1 (Chi3L1) is a Human protein synthetized by inflammatory cells. Its serum level increases in case of autoimmune diseases, and especially during multiple sclerosis (MS). There is a ne...
Eligibility Criteria
Inclusion
- Relapsing-onset multiple sclerosis according to the 2017 McDonald criteria
- Blood and cerebrospinal fluid samples collected at diagnostic assessment from 2012 January 1st and kept in the Centre de Ressources Biologiques Lorrain
- First platform disease modifying drugs : interferon-Beta, dimethyl fumarate or teriflunomide, introduced during the first 3 months after the diagnostic assessment
- Disease modifying drugs maintained at least 3 months
- Follow-up during at least 15 months after the first disease modifying drug initiation
- At least one brain magnetic resonance imaging with gadolinium injection between months 3 and 15 after disease modifying drug initiation
Exclusion
- Objection to the use of personal data for research purpose
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT04289675
Start Date
January 1 2012
End Date
December 1 2019
Last Update
March 9 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.